AIM: Our study aimed to assess expression of L1 cell adhesion molecule (L1CAM) in early-stage cervical squamous-cell cancer as a prognostic factor. PATIENTS AND METHODS: This retrospective, single-institution study included 154 patients who underwent radical hysterectomy for early-stage squamous cell cervical cancer between 2007 and 2017. Tumor samples from 154 patients were available for L1CAM analysis by immunohistochemistry. Among all patients, radical abdominal hysterectomy was performed in 144 cases. RESULTS: L1CAM expression was positive in 24 tumors (15.6%) of the whole group. In relation to the grade of differentiation and the presence of lymphovascular invasion, L1CAM expression did not show an association (p=0.154 and p=0.306, respectively). The disease-free interval and overall survival also did not significantly differ between L1CAM-positive and L1CAM-negative cases (p=0.427 and p=0.240, respectively). For histopathological characteristics, L1CAM-positive cases had a significantly higher median tumor size (p=0.015). Even in the selected group of 115 cases without nodal infiltration, L1CAM status had no effect on the relapse rate during follow-up. CONCLUSION: Our study did not confirm the results of previous studies showing L1CAM expression to be a negative prognostic factor in cervical cancer. In our study, increased L1CAM expression in early-stage squamous-cell cervical cancer was not associated with adverse prognosis regarding disease recurrence, disease-free survival, nor overall survival. L1CAM expression was correlated only with the size of the tumor.

Department of Applied Mathematics Faculty of Electrical Engineering and Computer Science VSB Technical University of Ostrava Ostrava Poruba Czech Republic

Department of Clinical and Molecular Pathology and Medical Genetics University Hospital Ostrava Ostrava Poruba Czech Republic

Department of Deputy Director for Science Research and Education University Hospital Ostrava Ostrava Poruba Czech Republic

Department of Obstetrics and Gynecology Gynecological Oncology Centre University Hospital Ostrava Ostrava Poruba Czech Republic

Department of Obstetrics and Gynecology Gynecological Oncology Centre University Hospital Ostrava Ostrava Poruba Czech Republic;

Zobrazit více v PubMed

World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2020: Estimated cancer incidence, mortality and prevalence worldwide in 2020. Available from https://gco.iarc.fr/ [Last accessed on April 10, 2023]

Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021;155 Suppl 1(Suppl 1):28–44. doi: 10.1002/ijgo.13865. PubMed DOI PMC

Cibula D, Pötter R, Planchamp F, Avall-lundqvist E, Fischerova D, Haie Meder C, Köhler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, Mccluggage WG, Mccormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer. 2018;28(4):641–655. doi: 10.1097/IGC.0000000000001216. PubMed DOI

Brümmendorf T, Rathjen FG. Cell adhesion molecules 1: Immunoglobulin superfamily. Protein Profile. 1995;2(9):963–1110. PubMed

Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular biology of the cell, fourth edition. New York, NY, USA, Garland Science. 2002

Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S, Altevogt P. L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr. 2012;6(4):374–384. doi: 10.4161/cam.20832. PubMed DOI PMC

Samatov TR, Wicklein D, Tonevitsky AG. L1CAM: Cell adhesion and more. Prog Histochem Cytochem. 2016;51(2):25–32. doi: 10.1016/j.proghi.2016.05.001. PubMed DOI

Mrazkova B, Dzijak R, Imrichova T, Kyjacova L, Barath P, Dzubak P, Holub D, Hajduch M, Nahacka Z, Andera L, Holicek P, Vasicova P, Sapega O, Bartek J, Hodny Z. Induction, regulation and roles of neural adhesion molecule L1CAM in cellular senescence. Aging (Albany NY) 2018;10(3):434–462. doi: 10.18632/aging.101404. PubMed DOI PMC

Altevogt P, Ben-ze’ev A, Gavert N, Schumacher U, Schäfer H, Sebens S. Recent insights into the role of L1CAM in cancer initiation and progression. Int J of Cancer. 2020;147(12):3292–3296. doi: 10.1002/ijc.33177. PubMed DOI

Raveh S, Gavert N, Ben-Ze’ev A. L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett. 2009;282(2):137–145. doi: 10.1016/j.canlet.2008.12.021. PubMed DOI

Altevogt P, Doberstein K, Fogel M. L1CAM in human cancer. Int J Cancer. 2016;138(7):1565–1576. doi: 10.1002/ijc.29658. PubMed DOI

Angiolini F, Cavallaro U. The pleiotropic role of L1CAM in tumor vasculature. Int J Mol Sci. 2017;18(2):254. doi: 10.3390/ijms18020254. PubMed DOI PMC

Adiga D, Eswaran S, Pandey D, Sharan K, Kabekkodu SP. The molecular landscape of recurrent cervical cancer. Crit Rev Oncol Hematol. 2021;157:103178. doi: 10.1016/j.critrevonc.2020.103178. PubMed DOI

Zhou X, Zhang H, Han X. Role of epithelial to mesenchymal transition proteins in gynecological cancers: pathological and therapeutic perspectives. Tumour Biol. 2014;35(10):9523–9530. doi: 10.1007/s13277-014-2537-1. PubMed DOI

Polyak K, Brisken C, Yang J, Weinberg RA. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–715. doi: 10.1016/j.cell.2008.03.027. PubMed DOI PMC

Ring A, Kim YM, Kahn M. Wnt/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev Rep. 2014;10(4):512–525. doi: 10.1007/s12015-014-9515-2. PubMed DOI PMC

Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A, Tilgen W, Reichrath J, Georg T, Altevogt P, Gutwein P. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett. 2003;189(2):237–247. doi: 10.1016/s0304-3835(02)00513-x. PubMed DOI

Alexandrescu DT, Lisa Kauffman C, Jatkoe TA, Hartmann DP, Vener T, Wang H, Derecho C, Rajpurohit Y, Wang Y, Palma JF. Melanoma-specific marker expression in skin biopsy tissues as a tool to facilitate melanoma diagnosis. J Invest Dermatol. 2010;130(7):1887–1892. doi: 10.1038/jid.2010.61. PubMed DOI

Boo Y, Park J, Kim J, Chae Y, Min B, Um J, Moon H. L1 Expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol. 2007;14(5):1703–1711. doi: 10.1245/s10434-006-9281-8. PubMed DOI

Doberstein K, Wieland A, Lee SBB, Blaheta RAA, Wedel S, Moch H, Schraml P, Pfeilschifter J, Kristiansen G, Gutwein P. L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis. 2011;32(3):262–270. doi: 10.1093/carcin/bgq249. PubMed DOI

Geismann C, Morscheck M, Koch D, Bergmann F, Ungefroren H, Arlt A, Tsao MS, Bachem MG, Altevogt P, Sipos B, Fölsch UR, Schäfer H, Müerköster SS. Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer. Cancer Res. 2009;69(10):4517–4526. doi: 10.1158/0008-5472.CAN-08-3493. PubMed DOI

Bosse T, Nout R, Stelloo E, Dreef E, Nijman H, Jürgenliemk-schulz I, Jobsen J, Creutzberg C, Smit V. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results. Eur J Cancer. 2014;50(15):2602–2610. doi: 10.1016/j.ejca.2014.07.014. PubMed DOI

Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M, Altevogt P. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003;362(9387):869–875. doi: 10.1016/S0140-6736(03)14342-5. PubMed DOI

Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K. L1CAM as a prognostic marker in stage I endometrial cancer: A validation study. BMC Cancer. 2016;16:596. doi: 10.1186/s12885-016-2631-4. PubMed DOI PMC

Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C, ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16–41. doi: 10.1093/annonc/mdv484. PubMed DOI

Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Abdel Azim S, Müller-Holzner E, Ben-Arie A, Van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M. L1CAM in early-stage type I endometrial cancer: Results of a large multicenter evaluation. J National Cancer Institute. 2013;105(15):1142–1150. doi: 10.1093/jnci/djt144. PubMed DOI

Klat J, Mladenka A, Dvorackova J, Bajsova S, Simetka O. L1CAM as a negative prognostic factor in endometrioid endometrial adenocarcinoma FIGO stage IA-IB. Anticancer Res. 2019;39(1):421–424. doi: 10.21873/anticanres.13128. PubMed DOI

Schrevel M, Corver WE, Vegter ME, Ter Haar NT, Dreef EJ, Beltman JJ, Kenter G, Bosse T, de Kroon CD, Jordanova ES. L1 cell adhesion molecule (L1CAM) is a strong predictor for locoregional recurrences in cervical cancer. Oncotarget. 2017;8(50):87568–87581. doi: 10.18632/oncotarget.20976. PubMed DOI PMC

Mancusi De Carvalho JP, Salim RC, Carvalho FM, Nogueira Dias Genta ML, Baracat EC, Carvalho JP. L1 cell adhesion molecule (L1CAM) in stage IB cervical cancer: distinct expression in squamous cell carcinomas and adenocarcinomas. J Clin Pathol. 2020;73(11):748–753. doi: 10.1136/jclinpath-2020-206500. PubMed DOI

Elfeky M, Harb O, El Shafaay B, Obaya A, Awd A, Alkilany M, Gertallah L. Prognostic and clinicopathological implications of NUSAP1, MELK and L1CAM immunohistochemical expression in cervical cancer. Middle East J Cancer. 2021;12(2):172–182.

Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynecol Obstet. 2018;143:22–36. doi: 10.1002/ijgo.12611. PubMed DOI

Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379(20):1895–1904. doi: 10.1056/NEJMoa1806395. PubMed DOI